ACADIA Pharmaceuticals (ACAD) Competitors

Qiagen (NYSE:QGEN) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, community ranking, dividends and institutional ownership.

Is QGEN or ACAD more profitable?

ACADIA Pharmaceuticals has a net margin of 13.83% compared to Qiagen's net margin of 4.73%. ACADIA Pharmaceuticals' return on equity of 25.83% beat Qiagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	4.73%	13.43%	8.10%
ACADIA Pharmaceuticals	13.83%	25.83%	14.71%

Do analysts recommend QGEN or ACAD?

Qiagen presently has a consensus target price of $50.88, indicating a potential upside of 16.53%. ACADIA Pharmaceuticals has a consensus target price of $25.56, indicating a potential upside of 53.90%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe ACADIA Pharmaceuticals is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60
ACADIA Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.65

Which has better valuation & earnings, QGEN or ACAD?

Qiagen has higher revenue and earnings than ACADIA Pharmaceuticals. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$1.97B	5.07	$341.30M	$0.39	111.95
ACADIA Pharmaceuticals	$726.44M	3.80	-$61.29M	$0.78	21.30

Does the MarketBeat Community believe in QGEN or ACAD?

ACADIA Pharmaceuticals received 645 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 73.20% of users gave ACADIA Pharmaceuticals an outperform vote while only 60.78% of users gave Qiagen an outperform vote.

Company	Underperform	Outperform
Qiagen	Outperform Votes 248 60.78%	Underperform Votes 160 39.22%
ACADIA Pharmaceuticals	Outperform Votes 893 73.20%	Underperform Votes 327 26.80%

Do institutionals and insiders believe in QGEN or ACAD?

70.0% of Qiagen shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 28.3% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Which has more risk & volatility, QGEN or ACAD?

Qiagen has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500.

Does the media prefer QGEN or ACAD?

In the previous week, ACADIA Pharmaceuticals had 1 more articles in the media than Qiagen. MarketBeat recorded 17 mentions for ACADIA Pharmaceuticals and 16 mentions for Qiagen. ACADIA Pharmaceuticals' average media sentiment score of 1.06 beat Qiagen's score of 0.89 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	8 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	9 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ACADIA Pharmaceuticals beats Qiagen on 13 of the 18 factors compared between the two stocks.